Company* |
University/ |
Type Of Agreement |
Product Area |
Details (Date) |
| ||||
AEterna Zentaris |
Tulane University |
License and collaboration agreement |
AEterna obtained worldwide, exclusive rights to develop and commercialize the GH-RH antagonists for all potential indications, including cancer and endocrine disorders |
AEterna will provide Tulane with research funding, an up-front fee and milestone payments, as well as potential royalties (10/27) |
| ||||
Alba |
University of Maryland |
License agreement |
Alba acquired rights to intellectual property surrounding the zonulin pathway |
The license is exclusive for all applications excluding human clinical diagnostics; Alba will sponsor further work at the university; further terms were not disclosed (8/30) |
| ||||
Alfacell Corp. |
National Institutes of Health |
License agreement |
A humanized, single-chain form of a B-cell-specific monoclonal antibody |
Alfacell gets rights to evaluate commercial applications for the antibody under undisclosed terms (9/15) |
| ||||
Alnylam |
Max Planck Society (Germany) |
License agreemeent |
They coexclusively licensed technology related to therapeutic uses of microRNA |
Isis and Alnylam in March entered a collaboration to develop RNAi therapeutics; terms of their deal with Max Planck were not disclosed (10/19) |
| ||||
AVI BioPharma |
Centers for Disease Control and Prevention |
Cooperative Research and Development Agreement |
Deal for further testing of AVI's Neugene antisense therapeutics |
The two-year deal focuses on drugs for the Dengue virus, for which preliminary studies have shown effectiveness (8/24) |
| ||||
AVI BioPharma |
U.S. Army Medical Research Institute of Infectious Diseases |
Cooperative Research and Development Agreement |
To test AVI's Neugene antisense therapeutics against potential bioterror agents |
Terms of the five-year deal involving several viruses, bacteria and and toxins were not disclosed (8/10) |
| ||||
Benitec Ltd. |
Stanford University |
License agreement |
Benitec gets rights to Minicircle DNA delivery technology for all RNAi therapeutic uses |
Benitec also gained sublicensing rights under the exclusive deal, terms of which were not disclosed (10/18) |
| ||||
Benitec Ltd. |
City of Hope |
Sponsored research agreement |
Deal on Benitec's ddRNAi technology for developing an HIV drug |
The deal marks the first one for City of Hope in which it will offer development services; terms were not disclosed (8/25) |
| ||||
|
Bioheart Inc.*
|
University of Florida |
Collaboration |
To develop a stem cell-recruiting myoblast technology with the addition of controlled release of angiogenic growth factors |
The technology will target the improvement of blood supply for recovering scarred heart tissue damaged from a heart attack (8/13) |
| ||||
Bionomics Ltd. |
Emory University |
Collaboration |
To study genetic variations associated with severe myoclonic epilepsy of infancy |
They will jointly own intellectual property arising from the work, while Bionomics will have exclusive commercialization rights (9/20) |
| ||||
BioVeris Corp. |
Children's Hospital & Research Center at Oakland |
Exclusive option agreement |
The option covers a vaccine candidate for Neisseria meningitidis serogroup B, which causes meningitis |
BioVeris would sponsor up to $800,000 of research at CHRCO over two years and pay license fees and potential milestones and royalties (10/19) |
| ||||
BTG plc |
University of Illinois at Chicago |
License agreement |
To further develop a drug for treating sleep apnea |
BTG will fund research in exchange for exclusive rights to resulting intellectual property (9/28) |
| ||||
Callisto |
University of Texas M.D. Anderson Cancer Center |
License agreement |
Callisto got rights to Annamycin, an anthracycline drug for leukemia |
Callisto intends to initiate a Phase IIb trial in 1H:05; terms of the deal were not disclosed (9/7) |
| ||||
Cellomics Inc.* |
The National Center for Drug Screening (China) |
Collaboration |
Deal designed to expand the application of high-content screening in China |
Cellomics will help incorporate its technologies into research programs at the center; terms were not disclosed (9/2) |
| ||||
Chiron Corp. |
German Red Cross |
License agreement |
The Red Cross can use Chiron's HIV-1 and hepatitis C virus technology in molecular probe blood screening |
Terms were not disclosed; the license runs through 2008; terms also cover potential past infringements (10/1) |
| ||||
CombinatoRx |
Accelerate Brain Cancer Cure |
Research collaboration |
To identify multi-target drugs for treating brain cancer |
CombinatoRx will get research funding from ABC2, and all rights to all products discovered in the collaboration (9/27) |
| ||||
CombinatoRx |
Spinal Muscular Atrophy Foundation |
Collaboration |
To identify novel combination drugs for treating spinal muscular atrophy |
CombinatoRx will receive two years of R&D funding and own all rights to resulting products; it also could earn milestone payments and increased funding (9/13) |
| ||||
CompuCyte |
National University of Singapore |
Collaboration |
To study cell death-inducing activity of small molecules for cancer and other diseases |
NUS will provide compounds for which CompuCyte will develop assays and perform cell- based analysis of their effect on cells (8/5) |
| ||||
Critical |
University of Florida |
License agreement |
CTI licensed a patent covering a family of compounds known as cinnamylidene-anabaseines |
The compounds target and stimulate the nicotinic alpha-7 cholinergic receptor and will be tested in inflammatory diseases; terms were not disclosed (9/9) |
| ||||
Crucell NV |
International AIDS Vaccine Initiative |
License agreement |
To develop an AIDS vaccine based on Crucell's AdVac technology |
Crucell expects to receive development funding along with up-front, annual and milestone payments, as well as royalties on any HIV vaccine sales (9/14) |
| ||||
CuraGen Corp. |
National Cancer Institute |
Clinical trials agreement |
The NCI will sponsor clinical trials evaluating PXD101 in various cancers |
The drug, already in Phase I trials, is being jointly developed with TopoTarget A/S (8/24) |
| ||||
CytoGenix Inc. |
Baylor College of Medicine |
Research agreement |
To test a CytoGenix antimicrobial agent against a strain of S. aureus bacteria |
Baylor researchers will conduct mice and cell studies for CytoGenix under undisclosed terms (10/21) |
| ||||
Dynavax |
Riken Institute (Japan) |
Collaboration |
To develop cedar tree allergy therapeutics using the company's ISS-based platform |
Dynavax will apply its expertise in immunostimulatory sequence- based products to the effort, terms of which were not disclosed (10/18) |
| ||||
Generex |
U.S. Army |
Collaborative Research and Development Agreement |
To advance HER-2/neu vaccine efforts for breast cancer cells |
Generex's Antigen Express subsidiary entered the deal with the Uniformed Services University of the Health Sciences and the Henry M. Jackson Foundation for the Advancement of Military Medicine Inc. to work with the Army (9/28) |
| ||||
Generex |
Fred Hutchinson Cancer Research Center |
Collaboration |
To test the potency of a peptide vaccine for melanoma in stimulating patients' immune cells |
Generex's Antigen Express subsidiary will work with Cassian Yee at the center on what is expected to be final preclinical work on the product (9/15) |
| ||||
Generex |
Massachusetts General Hospital |
Collaboration |
To use modified peptide antigens to stimulate immunity to HIV |
Generex's Antigen Express subsidiary will work with MGH on Ii-Key/HIV MHC Class II epitope hybrids (8/18) |
| ||||
Genome |
Institut Pasteur (France) |
Partnership |
The institute gains access to the tools on the firm's functional genomics platform |
The deal applies to research programs only; terms were not disclosed (8/1)# |
| ||||
GeoVax Inc.* |
Emory University and government organizations |
License agreement |
GeoVax got a license to AIDS vaccine technologies and patents |
The technology was developed through research with Emory, the National Institutes of Health and the Centers for Disease Control and Prevention (9/17) |
| ||||
GNI Ltd.* |
University of Cambridge (UK) |
License agreements |
GNI got rights to targets in the areas of angiogenesis and inflammation |
They also entered a two-year deal to build on the work covered in the exlusive licenses; terms were not disclosed (10/18) |
| ||||
GTC |
U.S. Army Medical Research Institute of Infectious Diseases |
Cooperative Research and Development Agreement |
To evaluate ATryn in hemorrhagic diseases resulting from infections of the Ebola and Marburg viruses |
GTC will supply ATryn, its recombinant form of human antithrombin, for preclinical studies by the USAMRIID; terms of the two- year deal were not disclosed (10/18) |
| ||||
Iconix |
Brigham and Women's Hospital/Harvard Medical School |
Agreement |
Iconix will support research on gene-expression patterns in patients with neurological diseases |
The goal is to validate gene-expression changes in human peripheral blood for diagnostics, prognostics and drug response (9/20) |
| ||||
Illumina Inc. |
North American Rheumatoid Arthritis Consortium |
Contract agreement |
For a two-phase genotyping study to identify genes associated with rheumatoid arthritis |
The first phase will involve genetic mapping of patient samples; the second phase is for mapping of specific candidate gene regions (9/16) |
| ||||
Illumina Inc. |
The Wellcome Trust Centre for Human Genetics (UK) |
Service agreement |
Illumina will generate more than 25 million mouse genotypes for the center |
The Wellcome Trust will use SNP variants to search for quantitative trait loci that contribute to variation across traits relevant to human disease, and make the information freely available to other researchers (8/12) |
| ||||
Indian Creek |
Summa Health Systems |
License agreement |
ICMT exclusively licensed rights to Apatone, a cancer drug designed to selectively kill cancer cells |
Apatone was developed by researchers at Summa, universities and hospitals; terms of the deal were not disclosed (8/30) |
| ||||
Integrated |
U.S. Navy |
R&D agreement |
For a Phase I trial of a plant-derived oral anthrax vaccine |
IBP's NuCycle Therapy Inc. subsidiary will work with the Navy on the vaccine designed to boost immune responses (9/20) |
| ||||
Invitrogen |
The UK Medical Research Council (UK), RZPD (Germany) and Open Biosystems |
Supply agreements |
The centers got access to Invitrogen's Gateway Technology and clones |
Government and academic researchers can create and distribute clones from the technology without paying royalties or license fees; terms of the deals were not disclosed (9/29) |
| ||||
Juvaris |
Penn State University |
Collaboration |
To develop immunostimulant and vaccine approaches for treating AML |
Juvaris technology will be tested in rodent tumor models created at Penn State to evaluate the impact on acute myeloid leukemia (9/28) |
| ||||
Lynx |
American Type Culture Collection |
Service agreement |
To study gene expression in certified human embryonic stem cells |
Lynx will receive payments for genomics services using its MPSS technology for analysis of gene expression (10/6) |
| ||||
Lynx |
Roswell Park Cancer Institute |
Service agreement |
Deal to use Lynx's Massively Parallel Signature Sequencing technology to study the transcriptional regulation of renin |
Lynx will receive payment for genomics discovery services it performs on samples provided (8/12) |
| ||||
Medicure Inc. (Canada; TSE:MPH) |
Loyola University Stritch School of Medicine |
Research agreement |
To advance development of the anti-thrombotic candidate MC-45308 |
In vivo preclinical efficacy studies will be done at Loyola under undisclosed terms (10/6) |
| ||||
Metabolon |
Massachusetts General Hospital |
Collaboration |
A biomarker study in amyotrophic lateral sclerosis to develop a diagnostic test |
The work is being funded under a grant from the National Institute of Neurological Disorders and Stroke (8/9) |
| ||||
Mologen AG (Germany; FSE:MGNG) |
Max Planck Institute for Infection Biology (Germany) |
Collaboration |
To develop a preventive DNA sub-unit vaccine against tuberculosis |
The intent is to develop a booster following vaccination with BCG; terms of the deal were not disclosed (10/9) |
| ||||
Mologen AG (Germany; FSE:MGNG) |
Biopharmaceutical R&D Center of Jinan University (China) |
Joint venture |
They will use Mologen's dSLIM technology to treat and prevent infectious diseases in China |
A third partner provided funding for the venture, which also will develop DNA medicines from the DNABarrier family against infectious diseases (8/26) |
| ||||
Morphotek Inc.* |
U.S. Army Medical Research Institute of Infectious Diseases |
Cooperative Research and Development Agreement |
To develop products to detect and treat infectious diseases from biowarfare pathogens |
Morphotek will apply its technologies to develop fully human antibodies that specifically target high-priority pathogenic agents (9/27) |
| ||||
OriGene |
Structural Genomics Consortium (Canada and the UK) |
Access agreement |
The consortium gains access to the TrueClone collection of human cDNA clones for use in structural genomics |
The consortium members are at Oxford University and the University of Toronto; terms were not disclosed (8/10) |
| ||||
Osmotics |
Brigham Young University |
License agreement |
Osmotics got rights to a family of compounds named cationic steroid antibiotics |
The worldwide, exclusive license also covers methods for treating antibiotic-resistant bacterial infections; terms were not disclosed (10/18) |
| ||||
Oxford Biomedica plc (UK: LSE:OXB) |
Massachusetts General Hospital, Boston University and Dana-Farber Cancer Institute |
Access agreement |
Oxford got extended access to the family of cytochrome P450 enzymes in cancer gene therapy |
The original license deal was in 1997 and it was extended in 2000; the extension covers the use of the gene therapy product MetXia in pancreatic cancer (9/17) |
| ||||
Pharming |
U.S. Army |
Evaluation agreement |
The Army will evaluate Pharming's recombinant human fibrinogen product |
The Army will look at tissue sealant and therapeutic applications, work that could lead to a larger deal (9/20) |
| ||||
Pharminox Ltd.* (UK) |
Cancer Research Technology Ltd. (UK) |
License agreement |
Pharminox got rights to Phortress, a cancer drug in Phase I trials |
Pharminox gained a 12-month option to license the drug and related compounds (8/12) |
| ||||
Pluristem Life |
Israel Institute of Technology |
Collaboration |
To develop Pluristem's technology for expanding stem cells collected from umbilical cords |
The Office of the Chief Scientist in Israel is providing financing for the collaboration; terms were not disclosed (8/16) |
| ||||
Power3 Medical Products Inc. (OTC BB:PWRM) |
Mercy Women's Center |
Research agreement |
To identify protein biomarkers for the early indication of breast cancer |
The center will provide Power3 with up to 600 blood serum samples from healthy subjects and breast cancer patients (9/20) |
| ||||
Power3 Medical Products Inc. (OTC BB:PWRM) |
Baylor College of Medicine |
Research agreement |
For discovery of biomarkers in serum and plasma targeting metabolic syndrome and associated disorders |
Terms of the deal were not disclosed (8/31) |
| ||||
ProlX |
Universities of Arizona and Pittsburgh and the Burnham Institute |
License agreement |
ProIX licensed worldwide rights to the phosphatidylino- |
The technology was developed through a National Cancer Institute program and the rights were jointly owned by the institutes, which would get revenues if ProlX successfully commercializes any of the licensed agents (8/19) |
| ||||
Protox Therapeutics Inc. (Canada; CDNX:PRX) |
Johns Hopkins University and the University of Victoria (Canada) |
License agreement |
Protox gained worldwide rights to commercialize a genetically modified Aerolysin protein developed as a targeted therapy for prostate cancer |
Terms include an up-front licensing fee and milestone and royalty payments (10/25) |
| ||||
RiboNovix Inc.* |
Wayne State University |
License agreement |
License for a genetic system that allows mutational analysis of ribosomal RNA in living cells |
Terms of the exclusive license agreement were not disclosed (10/5) |
| ||||
Samaritan |
Georgetown University |
License agreement |
The license covers a drug candidate (SP-08) for Alzheimer's disease |
Samaritan gained an exclusive worldwide license under undisclosed terms (9/16) |
| ||||
Sequenom |
Translational Genomics Research Institute |
Research agremeent |
Sequenom will provide TGen access to targets associated with a predisposition to skin cancer |
TGen will further validate the genes against its expression databases; products would be jointly owned and commercialized (8/31) |
| ||||
Sequenom |
University of Tuebingen (Germany) |
Agreement |
The university will use the MassARRAY platform to validate microarray data |
The university also will explore gene- xpression levels in various neurodegenerative diseases and cancers, and serve as a Mass- ARRAY Compact reference site (8/17) |
| ||||
Sequenom |
The Chinese University of Hong Kong |
Collaboration |
To further develop prenatal diagnostic applications on the MassARRAY platform |
The agreement includes the placement of a MassARRAY DNA analysis system at the university (8/10) |
| ||||
Thermo Electron |
Massachusetts General Hospital |
Collaboration |
Agreement to focus on the development of mass spectrometry- based technologies dedicated to the discovery of protein biomarkers |
The project is known as the Biomarker Research Initiatives in Mass Spectrometry Center (10/27) |
| ||||
7TM Pharma A/S*, TopoTarget A/S* and Danisco A/S* (all of Denmark) |
The Danish Technological Institute and the University of Southern Denmark |
Consortium formation |
To develop advanced protein-analysis methods for research in drug development and food ingredients |
The Biological Interaction Analysis consortium has a budget of $6.8M for the next three years, of which $2.4M came from Denmark's Ministry of Science, Technology and Innovation (10/11) |
| ||||
TransForm |
University of South Florida |
Collaboration and license agreement |
To design and discover co-crystal structures to enhance drug properties |
TransForm also got a license to USF for exclusive rights to new pharmaceutical co- crystal forms discovered at USF; terms were not disclosed (8/11) |
| ||||
Vernalis plc (UK; VNLS) |
Cancer Research Technology Ltd. and The Institute of Cancer Research (both in the UK) |
License agreement |
Vernalis got exclusive worldwide rights to an anticancer Hsp90 inhibitor program |
Vernalis will pay the UK centers an up-front fee as well as potential milestone, royalty and sub-licensing payments (9/29) |
| ||||
Ziopharm Inc.* |
University of Texas M. D. Anderson Cancer Center and Texas A&M University |
Worldwide license agreement |
A new class of organic arsenicals, which will be developed for various cancers |
Ziopharm plans to begin Phase I trials in 1Q:05; in the class, an arsenic atom is complexed to organic molecules; terms were not disclosed (9/15) |
Notes: | ||||
This chart does not include grants or contract awards, or agreements between biotech companies and clinical trial centers. | ||||
* Denotes privately held company. | ||||
# Item occurred before the time frame of this chart but was not included in the previous chart. | ||||
@ Some institutions listed have for-profit components. They are located in the U.S. unless otherwise noted. | ||||
Unless otherwise noted, shares are traded on the Nasdaq exchange. | ||||
AMEX = American Stock Exchange; ASX = Australian Stock Exchange; CDNX = Canadian Venture Exchange; FSE = Frankfurt Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange. | ||||
To read more on related topics, click on one of the words below.